TICLOPIDINE
It is a potent inhibitor of platelet aggregation induced by adenosine disphate and it also inhibits aggregation due to collagen, adrenaline, arachidonic acid, thrombin and platelet activating factor. When taken orally. Ticlopidine causes a time and dose dependent inhibitation of both platelet aggregation and release of platelet granule constituents, as well as prolongation of bleeding time.Cerebrovascular disease such as transient ischaemic attacks (TIA), reversible ischaemic neurological deficit (RIND), stroke; coronary artery disease such as unstable angina, coronary artery by-pass grafts (CABG) secondary prevention of myocardial infarction; extracorporal shunts such as for haemodialysis and diabetic retinopathy.
250mg twice a day with meals.
Hypersensitivity,haemorrhagic diathesis,gastrointestinal ulcers,liver dysfunction, presence of haematopoietic disorders
Risk of increased bleeding from trauma, surgery, or pathological conditions. Paediatrics: Contraindicated. Pregnancy: Contraindicated. May cause uterine bleeding. Lactation: The drug passes into breast milk may affect the baby. Elderly: Increases risk or adverse reactions.
Diarrhoea, nausea, vomiting, G.I. pain, skin rashes,vertigo, cholestatic jaundice.
Risk of haemorrhage increased with aspirin and oral anticoagulants, increase in plasma level of ticlopidine with cimetidine, increase in theophylline half-life, decreases plasma digoxin levels.
